Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glowing dye could help surgeons spot hidden brain tumor cells

NCT ID NCT04743310

Diagnosis Sponsor: John Yu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether a fluorescent dye called tozuleristide, given before surgery, can make brain tumor tissue glow under a special imaging system. Surgeons can then see and remove more of the tumor while sparing healthy brain. The trial enrolls adults with certain types of brain tumors who are scheduled for surgery. The goal is to see how accurately the dye identifies tumor tissue and whether it helps achieve more complete removal.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tozuleristide
What this could lead to
If successful, this approach could help surgeons remove brain tumors more completely by making tumor tissue glow during surgery.
What could go wrong
This is a small, early-phase study. The dye may not work for all tumor types, and there is a risk of allergic reaction or other side effects. The technique may not improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Sep 2021

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary malignant central nervous system tumor for which maximal safe resection is indicated OR MRI obtained within 30 days of study enrollment documents a measurable lesion consistent with a primary schwannoma enhancing tumor in the cerebellopontine angle for which maximal safe resection is indicated. * Adequate renal and liver function * Subjects with prior therapy are eligible provided they have recovered from any acute toxic effects of prior therapy and have sufficient time interval prior to enrollment. Exclusion Criteria: * Pregnant, breast-feeding, or planning to conceive a child within 30 days * Ongoing serious medical conditions such that participation in the study could put the subject at increased risk of worsening their condition * Subjects planned to undergo only a diagnostic biopsy procedure, without intent to resect tissue for therapeutic purposes * Subjects for whom radiographic evidence suggests a non-intra-axial primary brain tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central nervous system tumor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acoustic neuroma astrocytoma (excluding glioblastoma) brain cancer central nervous system cancer craniopharyngioma ependymoma glioblastoma glioma medulloblastoma meningioma Neoplasms, Germ Cell and Embryonal Pinealoma primary brain neoplasm spinal cord neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central nervous system tumor

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.